Request Demo
Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.
AcquisitionDrug Approval
BEDMINSTER, N.J., June 09, 2026 (GLOBE NEWSWIRE) --
Alembic Therapeutics, LLC
announces the acquisition of NUVESSA
®
(metronidazole vaginal gel 1.3%), an FDA-approved prescription medication indicated for the treatment of bacterial vaginal infections in females 12 years of age and older, from Exeltis USA, Inc. This acquisition represents an important milestone in Alembic Therapeutics’ ongoing commitment to expanding its women’s health portfolio and increasing patient access to proven treatment options. Through this transaction, Alembic Therapeutics assumes responsibility for the commercialization and distribution of NUVESSA in the United States.
NUVESSA is indicated for the treatment of bacterial vaginosis in females 12 years of age and older. NUVESSA is designed as a convenient single-dose, pre-filled disposable applicator, which delivers approximately 5g of gel containing 65mg of metronidazole, administered once a day at bedtime intravaginally. NUVESSA is contraindicated in persons who have shown hypersensitivity to metronidazole, parabens, any component of the formulation, or other nitroimidazole derivatives.
NUVESSA will continue to be available nationwide through retail and specialty pharmacy distribution channels. Healthcare providers can continue prescribing NUVESSA in accordance with the approved prescribing information for appropriate patients. The full prescribing information should be consulted for complete details regarding approved indications, dosing, administration, contraindications, warnings, and safety information.
Alembic Therapeutics is dedicated to delivering high-quality pharmaceutical products and innovative healthcare solutions that improve patient outcomes and expand access to care across multiple therapeutic categories.
Alembic Therapeutics, LLC
550 Hills Drive, Suite 110
Bedminster NJ 07921
908-569-7456 • Sales@alembictx.com
A photo accompanying this announcement is available at
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
WCLC 2026 Plenary Studies Clinical Evidence Review Report
Patsnap Synapse
ESC Congress 2026 Clinical Evidence Review: Seven Pivotal Trials, Guideline Updates, and AI Findings
Patsnap Synapse
Oligonucleotide Therapeutics Report: What Patent Intelligence Reveals About the Next Wave of Platform Competition
Patsnap Synapse
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!